texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Panhandle Clinical Trials

Texas Oncology cancer centers in the Texas Panhandle participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Texas Panhandle area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Texas Panhandle area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Texas Panhandle area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Texas Panhandle area and talk to you doctor to determine which clinical trial is right for you.

Bone Marrow Transplant

Indication: Bone Marrow Transplant

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Hematologic

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Miscellaneous

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Skin Cancer

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Urothelial Cancer

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Texas Oncology-Amarillo Cancer Center

Indication: Bone Marrow Transplant

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

No Phase

Indication: Bone Marrow Transplant

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Protocol for a research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries. View

Indication: Miscellaneous

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: PNH (Paroxysmal Nocturnal Hemoglobiniuria) Registry View

Indication: Hematologic

Location: Texas Oncology-Amarillo Cancer Center

Phase:

Title: Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry View

Phase II

Indication: Skin Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629) View

Indication: Urothelial Cancer

Location: Texas Oncology-Amarillo Cancer Center

Phase: II

Title: A Phase 2, Open-label, Single Agent, Multi-Center Study to Evaluate the Efficacy and Safety of a Pan-FGFR Tyrosine Kinase Inhibitor INCB054828 in Patients with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations (INCB View

Phase IV

Indication: Solid Tumors

Location: Texas Oncology-Amarillo Cancer Center

Phase: IV

Title: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001) View